Head & Neck


CIRB #H-29284/RTOG #R0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab For Locally-Advanced Resected Head and Neck Cancer

IRB #H-33141/CTSU #E3311: A Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

High Risk:

CIRB #H-32379/ RTOG #R1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck (temporary closure until 2017)

IRB #pend/ RTOG Foundation #R3504: Randomized Phase III Trial of Cisplatin-Based Chemoradiotherapy (CRT) +/- Nivolumab (Anti-PD-1) in Patients with Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (with Phase I Lead in) (not yet submitted to the IRB)


CIRB #H-33148/NRG #HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

Salivary Gland:

CIRB #H-35696/RTOG #R1008: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors (IRB approval pending)

Primary teaching affiliate
of BU School of Medicine